Biogen Inc. Stock price

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
219.4 USD +0.04% Intraday chart for Biogen Inc. -4.64% -15.21%
Sales 2024 * 9.48B Sales 2025 * 9.61B Capitalization 31.89B
Net income 2024 * 1.89B Net income 2025 * 2.27B EV / Sales 2024 * 3.64 x
Net Debt 2024 * 2.64B Net Debt 2025 * 413M EV / Sales 2025 * 3.36 x
P/E ratio 2024 *
16.6 x
P/E ratio 2025 *
14.1 x
Employees 7,570
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.07%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.04%
1 week-4.64%
Current month+1.11%
1 month+0.15%
3 months-12.36%
6 months-13.38%
Current year-15.21%
More quotes
1 week
216.80
Extreme 216.8
229.90
1 month
215.35
Extreme 215.35
230.22
Current year
215.35
Extreme 215.35
268.30
1 year
215.35
Extreme 215.35
319.76
3 years
187.16
Extreme 187.16
468.55
5 years
187.16
Extreme 187.16
468.55
10 years
187.16
Extreme 187.16
480.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 22-11-13
Director of Finance/CFO 60 20-08-14
Chief Operating Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 75 09-12-31
Director/Board Member 70 19-06-18
Chairman 64 10-01-02
More insiders
Date Price Change Volume
24-03-18 219.4 +0.04% 1,356,644
24-03-15 219.3 -0.14% 2,407,106
24-03-14 219.6 -3.06% 1,611,591
24-03-13 226.6 -0.35% 1,481,162
24-03-12 227.4 -1.18% 1,068,888

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (78.5%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (16.7%) ; - other (4.8%): primarily revenues from partnership agreements.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
219.4 USD
Average target price
299.6 USD
Spread / Average Target
+36.56%
Consensus
  1. Stock
  2. Equities
  3. Stock Biogen Inc. - Nasdaq